中文

CDMO Capacity Database

Global CXDMO bioreactor capacity comparison (as of 2026-10), covering sites, modalities and recent expansion. Companies without a published aggregate show reactor specs instead.

10Companies
1,125,000 LKnown capacity (sum)
2026-10As of

Samsung Biologics

KRX: 207940
845,000 L
HQ
Incheon, Korea
Source
https://samsungbiologics.com/services/biopharma-manufacturing ↗
Modalities
mAb双抗ADC重组蛋白mRNAFc 融合蛋白
Sites
  • BIO Campus I (Songdo)
  • Plant 5
  • Rockville, MD (美国)

BIO Campus I 605k + Plant 5 180k + 美国 Rockville 60k；2032 规划扩至 1,325k L（Campus II Plant 5-8）。

Expansion：收购多肽 CDMO PolyPeptide；规划 Bio Campus III。

RelatedSamsung Biologics Crosses $22B Cumulative Order Barrier; 845,000 L Capacity Leads the World →Samsung Biologics Targets CDMO Contracts Across Four Global Events in October →

WuXi Biologics

HKEX: 2269
260,000+ L（在产）
HQ
Shanghai
Source
https://www.wuxibiologics.com/mammalian/ds-manufacturing ↗
Modalities
mAb双抗ADC重组蛋白
Sites
  • 无锡
  • 上海
  • 成都
  • 杭州
  • 河北
  • 爱尔兰 Dundalk
  • 德国 Wuppertal
  • 美国 Worcester/Mass
  • 新加坡 Tuas

在产生物反应器 >260,000 L；2026 规划 >580,000 L（中/爱/美/德/新五国）。15 个 GMP 认证生产基地。

Expansion：新加坡 Tuas 大规模一次性生物反应器工厂、美国 MFG11/18 扩产；2026 规划 >580,000 L。

RelatedWuXi Biologics at CPHI Milan 2026: Empowering European Biomanufacturing via Integrated CRDMO & Global Dual Sourcing →WuXi Biologics Passes Another FDA GMP Inspection, Reinforcing Its Quality Track Record and Commercial Supply Reliability →WuXi Biologics H1 2026: Revenue RMB 11.8B, Up 18.4%; Adjusted Net Profit RMB 3.9B, Up 38.6% →

BioDlink

HKEX: 1875
单抗/抗体中间体 >20,000 L
HQ
Suzhou
Source
https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0821/2026082101237_c.pdf ↗
Modalities
mAb双抗ADC生物类似药
Sites
  • 苏州

苏州 50,000 m²；5 条单抗线 50–2,000 L 一次性；偶联 DS 3 线 20–500 L；DP 500 万瓶/年。

Expansion：被药明合联收购 61.47%，聚焦纯 play CDMO。

RelatedBioDlink's CDMO Business Accelerates: 14 New CMC Projects Signed, Backlog Reaches RMB 391M (+95.5% YoY) →BioDlink 2026 Interim Results: CDMO Revenue RMB 199M, Up 157% YoY, Now Part of the WuXi XDC Platform →

Lonza

SIX: LONN
未公开聚合（最大单厂 Vacaville 332,000 L）
HQ
Basel, Switzerland
Source
https://www.lonza.com/integrated-biologics/manufacturing/mammalian-drug-manufacturing ↗
Modalities
mAb生物偶联HPAPI细胞与基因治疗
Sites
  • Visp (瑞士)
  • Vacaville, CA (美国)
  • Portsmouth, NH (美国)
  • Porriño (西班牙)
  • Ibex (新加坡)
  • Stein (瑞士)
  • Oceanside (美国)
  • IBET (葡萄牙)

哺乳动物 6 个 cGMP 基地，生物反应器 1kL–25kL；Vacaville 332,000 L、Visp 大型哺乳动物 2026 商业化爬坡。

Expansion：Visp 大型哺乳动物 2026 商业化爬坡；出售 Capsules & Health Ingredients 转型 pure-play CDMO。

RelatedLonza to Sell Capsules & Health Ingredients (CHI) to Lone Star Funds for CHF 2.3B, Completing Pure-Play CDMO Pivot →Lonza Advances Preclinical Aseptic Spray Drying to Address High-Dose Biologics Delivery Challenges →Lonza and Asimov Collaborate to Advance In Vivo Lentiviral Vector Manufacturing →Lonza at Morgan Stanley: Advancing the Pure-Play CDMO Transition, with Focus on Growth and Cash →

AsymBio (Asymchem Biologics)

002821.SZ / 6821.HK（凯莱英）
未公开聚合（反应器 200–2,000 L 一次性）
HQ
Shanghai
Source
https://www.asymbio.com/gsdt/215.html ↗
Modalities
抗体双抗ADC/NDC重组蛋白
Sites
  • 张江 CBTI
  • 金山
  • 奉贤（上海）
  • 天津 payload-linker

张江 CBTI + 金山 + 奉贤三大基地；抗体 DS 200/500/2,000 L 一次性；偶联反应器 50/100/200/500 L；奉贤 130,000+ m²。

Expansion：奉贤商业化基地 2026-03 投产，完成「双基地 + 一中心」网络。

RelatedAsymBio Named 'Integrated Biologics CDMO Company of the Year in APAC 2026' →Asymchem H1 2026 (HK): Revenue RMB 3.19B, Up 20.1%; Peptide Capacity to Reach 69,000 L by Year-End →

Pharmaron Biologics

300759.SZ / 3759.HK
未公开聚合（生物反应器 200–4,000 L 一次性）
HQ
Beijing
Source
https://www.pharmaron.com/?p=24536 ↗
Modalities
mAb双抗重组蛋白AAV/慢病毒小分子/多肽/ADC
Sites
  • 绍兴
  • 宁波
  • San Diego (美国)
  • Liverpool (英国)
  • Cramlington (英国)

生物药 DS 200–4,000 L 一次性；CGT（利物浦）病毒载体 50–500 L；小分子 API 达 12,500 L。

Expansion：大分子 + CGT 双布局，全球一体化 CMC 网络。

RelatedPharmaron H1 2026: Revenue RMB 7.60B, Up 17.92%; New Order Intake Grows Over 30% →

Porton (Porton Pharma Solutions)

300363.SZ
生物药产能未公开（ATMP/偶联为重点）
HQ
Chongqing
Source
https://www.portonpharma.com/en/newsinfo/Porton_Successfully_Concludes_CPHI_Milan_2026_Showcasing_Integrated_CDMO_Capabilities_and_Connecting_for_Global_Pharma_Innovation ↗
Modalities
小分子多肽/寡核苷酸ADC/AOC/DACATMP(CGT)
Sites
  • 重庆
  • 上海
  • 美国 J-STAR

业务覆盖小分子、TIDES、生物药与偶联、ATMP（质粒/病毒载体/细胞治疗/mRNA-LNP）。

Expansion：一体化 DS-DP CDMO，覆盖临床到商业化全链。

RelatedPorton Pharma 2026 Interim Results: Revenue RMB 1.79B, Up 10% YoY; Continuing-Operations Profit Surges 329% →

WuXi XDC

HKEX: 2268
偶联反应器 200–2,000 L（抗体中间体）/ 偶联 DS 达 2,000 L
HQ
Shanghai / Wuxi
Source
https://www.jtc.gov.sg/about-jtc/news-and-stories/industry-news/wuxi-xdc-celebrates-gmp-release-of-singapore-site ↗
Modalities
ADC抗体中间体偶联制剂（DP 800 万瓶/年）
Sites
  • 无锡
  • 上海
  • 合肥
  • 苏州
  • 新加坡 Tuas

新加坡 BCM3 抗体中间体 200–2,000 L、偶联 DS 达 2,000 L；BCM4 偶联 DS 500 L；4 个中国基地 + 新加坡。

Expansion：新加坡首海外基地 2026-08 GMP 放行，全球双源网络成型。

RelatedWuXi XDC Celebrates GMP Release of Singapore Site, Ushering in a New Era of Global Expansion →WuXi XDC Out-Licenses WuXiTecan-2 Payload-Linker Technology Platform to Ona Therapeutics to Advance Novel ADC R&D →

WuXi AppTec *

603259.SH / 2359.HK
非生物药 CDMO（小分子 CRDMO + TIDES）
HQ
Shanghai
Source
https://www.wuxiapptec.com ↗
Modalities
小分子多肽/寡核苷酸 (TIDES)片段/制剂
Sites
  • 上海
  • 无锡
  • 常州
  • 美国
  • 以色列

以小分子/多肽/寡核苷酸 CRDMO 与实验室服务为主，生物药产能非核心。

Expansion：一体化 CRDMO 平台，覆盖发现到商业化。

RelatedTreating the 'King of Cancers': How New RAS Inhibitors Expand the Boundaries of Small-Molecule Drugs — 2026 Q3 Induced-Proximity Watch →WuXi AppTec H1 2026: Revenue RMB 28.9B, Up 38.9%; Full-Year Guidance Raised Across the Board →100% Retention Rate: How WuXi AppTec's Integrated Platform Helped Clients Secure Global Partnerships →

Insilico Medicine *

HKEX: 2257
非 CDMO（AI 药物发现平台）
HQ
Hong Kong / Boston
Source
https://insilico.com ↗
Modalities
AI 药物发现自研管线
Sites
  • 香港
  • Boston
  • 上海
  • Toronto

以 AI 平台发现候选药物并推进自研管线，非合同制造。

Expansion：自研管线推进临床（如 ISM3412、Rentosertib 等）。

RelatedBreaking the Safety Barrier: Insilico Medicine Nominates ISM1354, Next-Gen Small-Molecule GIPR Antagonist →World's First Generative AI-Discovered Drug Enters Phase III: Insilico Doses First Patient with Rentosertib →Insilico Launches "Longevity Vaccines" Research: Programming the Body's Own T Cells with Circular mRNA →

Notes

Figures are sourced from company websites, filings and official releases (as of 2026-10). 'Not aggregated' means no single total capacity is disclosed — only reactor specs are listed. Entries marked * are not biologics CDMOs (WuXi AppTec is small-molecule CRDMO-led; Insilico is AI drug discovery) and are shown for reference only.